2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-6-chloro-3-(2H)-pyridazinone | 142230-59-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-6-chloro-3-(2H)-pyridazinone
• 英文别名: 6-Chloro-2-[3-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)propyl]pyridazin-3-one
• CAS: 142230-59-9
• 化学式: C₁₆H₁₈ClN₃O₃
• 分子量: 335.79
• InChiKey: ZWGJGUSBCBFABI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,3-二氢-1,4-苯并二恶-2-甲胺 、 2-(3-chloro-1-propyl)-6-chloro-3(2H)-pyridazinone 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 2-[3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl]-6-chloro-3-(2H)-pyridazinone
  参考文献：
  名称：

  Synthesis, antihypertensive and α-adrenoceptor activity of novel 2-aminoalkyl-3(2H)-pyridazinones

  摘要：

  A number of 2-phenoxyalkylaminoalkyl- and 2-[1,4]benzodioxanylmethylaminoalkyl-3(2H)-pyridazinones were synthesized and tested for hypotensive and antihypertensive activity as well as for alpha-1- and alpha-2-adrenoceptor binding affinities. Some derivatives, eg 5.5, 5.9, 5.12, 6.4 and 6.10, showed strong hypotensive/antihypertensive effect and high affinity for alpha-2- and alpha-1-adrenoceptors. Compound 5.5 was selected for clinical study. In its mode of action a potassium channel opening activity may also be involved.

  DOI：

  10.1016/0223-5234(92)90098-l

文献信息

• Synthesis, antihypertensive and α-adrenoceptor activity of novel 2-aminoalkyl-3(2H)-pyridazinones
  作者：P Mátyus、J Kosáry、E Kasztreiner、N Makk、E Diesler、K Czakó、G Rabloczky、L Jaszlits、E Horváth、Z Tömösközi、G Cseh、E Horváth、P Arányi

  DOI：10.1016/0223-5234(92)90098-l

  日期：1992.3

  A number of 2-phenoxyalkylaminoalkyl- and 2-[1,4]benzodioxanylmethylaminoalkyl-3(2H)-pyridazinones were synthesized and tested for hypotensive and antihypertensive activity as well as for alpha-1- and alpha-2-adrenoceptor binding affinities. Some derivatives, eg 5.5, 5.9, 5.12, 6.4 and 6.10, showed strong hypotensive/antihypertensive effect and high affinity for alpha-2- and alpha-1-adrenoceptors. Compound 5.5 was selected for clinical study. In its mode of action a potassium channel opening activity may also be involved.